Shrimali R K, Mahata A, Reddy G D, Franks K N, Chatterjee S
Department of Radiation Oncology, Tata Medical Center, Kolkata, India.
Medical Physics, Tata Medical Center, Kolkata, India.
Clin Oncol (R Coll Radiol). 2016 Mar;28(3):185-97. doi: 10.1016/j.clon.2015.08.002. Epub 2015 Aug 29.
Intensity-modulated radiotherapy (IMRT) is being increasingly used for the treatment of non-small cell lung cancer (NSCLC), despite the absence of published randomised controlled trials. Planning studies and retrospective series have shown a decrease in known predictors of lung toxicity (V20 and mean lung dose) and the maximum spinal cord dose. Potential dosimetric advantages, accessibility of technology, a desire to escalate dose or a need to meet normal organ dose constraints are some of the factors recognised as supporting the use of IMRT. However, IMRT may not be appropriate for all patients being treated with radical radiotherapy. Unique problems with using IMRT for NSCLC include organ and tumour motion because of breathing and the potential toxicity from low doses of radiotherapy to larger amounts of lung tissue. Caution should be exercised as there is a paucity of prospective data regarding the efficacy and safety of IMRT in lung cancer when compared with three-dimensional conformal radiotherapy and IMRT data from other cancer sites should not be extrapolated. This review looks at the use of IMRT in NSCLC, addresses the challenges and highlights the potential benefits of using this complex radiotherapy technique.
尽管缺乏已发表的随机对照试验,但调强放射治疗(IMRT)在非小细胞肺癌(NSCLC)治疗中的应用越来越广泛。规划研究和回顾性系列研究表明,肺部毒性的已知预测指标(V20和平均肺剂量)以及脊髓最大剂量有所降低。潜在的剂量学优势、技术的可及性、提高剂量的愿望或满足正常器官剂量限制的需求是被认为支持使用IMRT的一些因素。然而,IMRT可能并不适用于所有接受根治性放疗的患者。将IMRT用于NSCLC的独特问题包括因呼吸导致的器官和肿瘤运动,以及低剂量放疗对大量肺组织产生的潜在毒性。由于与三维适形放疗相比,关于IMRT在肺癌中疗效和安全性的前瞻性数据较少,且不应外推来自其他癌症部位的IMRT数据,因此应谨慎使用。本综述探讨了IMRT在NSCLC中的应用,阐述了挑战,并强调了使用这种复杂放疗技术的潜在益处。